HBPCF (Helix BioPharma) E10: $-0.34 (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma E10?

Helix BioPharma HBPCF 28 E10 is $-0.34 as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Helix BioPharma's adjusted earnings per share data for the three months ended in Apr. 2026 was $-0.007. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.34 for the trailing ten years ended in Apr. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Helix BioPharma was 6.00% per year. The lowest was 1.20% per year. And the median was 3.60% per year.

As of today (2026-06-25), Helix BioPharma's current stock price is $1.71. Helix BioPharma's E10 for the quarter that ended in Apr. 2026 was $-0.34. Helix BioPharma's Shiller PE Ratio of today is .


Helix BioPharma  (OTCPK:HBPCF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Helix BioPharma E10 Related Terms


Helix BioPharma E10 Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma E10 Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.51 0.00 -0.37 -0.35 -0.24

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.24 -0.36 -0.34 -0.34

HBPCF vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Helix BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Shiller PE Ratio falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Helix BioPharma's adjusted earnings per share data for the three months ended in Apr. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.007/132.2623*132.2623
=-0.007

Current CPI (Apr. 2026) = 132.2623.

Helix BioPharma Quarterly Data

per share eps CPI Adj_EPS
201607 -0.115 101.844 -0.149
201610 -0.151 102.002 -0.196
201701 -0.114 102.318 -0.147
201704 -0.112 103.029 -0.144
201707 -0.039 103.029 -0.050
201710 -0.079 103.424 -0.101
201801 -0.121 104.056 -0.154
201804 -0.079 105.320 -0.099
201807 -0.076 106.110 -0.095
201810 -0.038 105.952 -0.047
201901 -0.075 105.557 -0.094
201904 -0.075 107.453 -0.092
201907 -0.076 108.243 -0.093
201910 -0.076 107.927 -0.093
202001 -0.076 108.085 -0.093
202004 -0.071 107.216 -0.088
202007 -0.074 108.401 -0.090
202010 -0.151 108.638 -0.184
202101 -0.079 109.192 -0.096
202104 -0.080 110.851 -0.095
202107 -0.080 112.431 -0.094
202110 -0.040 113.695 -0.047
202201 -0.040 114.801 -0.046
202204 -0.040 118.357 -0.045
202207 0.000 120.964 0.000
202210 -0.037 121.517 -0.040
202301 -0.037 121.596 -0.040
202304 -0.037 123.571 -0.040
202307 -0.083 124.914 -0.088
202310 -0.022 125.310 -0.023
202401 -0.015 125.072 -0.016
202404 -0.029 126.890 -0.030
202407 -0.080 128.075 -0.083
202410 -0.022 127.838 -0.023
202501 -0.021 127.443 -0.022
202504 -0.021 129.102 -0.022
202507 -0.007 130.287 -0.007
202510 -0.007 130.603 -0.007
202601 -0.007 130.366 -0.007
202604 -0.007 132.262 -0.007

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.34 mean?
Helix BioPharma (HBPCF) has a E10 of $-0.34 as of Apr. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Helix BioPharma and its competitors.
Is Helix BioPharma's E10 too high?
Helix BioPharma's current E10 is $-0.34. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's E10 compare to VRTX and REGN?
Helix BioPharma's E10 of $-0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current E10 is $-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current E10 of $-0.34. The current E10 is $-0.34. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current E10 is $-0.34 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price